The announcement notes that St Vincent's is prohibited from releasing price-sensitive data such as response rates via a video presentation, but it is not difficult to read between the lines.
Responses must be very good, otherwise Noxopharm would not initiate a randomised Phase 2 trial!
We will know the exact state of affairs when St Vincent's presents at a major conference in June. If Veyonda improves the performance of LuPSMA, which appears to be the case, then Novartis will be very interested indeed!
This is great news for prostate cancer patients; and for Noxopharm shareholders.
Ann: Principal Investigator Discusses LuPIN-1 Study, page-3
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $4.773K | 48.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20574 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 38542 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
